3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Extranodal NK-T-Cell
1
Interventions
fludarabine phosphate
4
Rituximab
4
Peripheral Blood Stem Cell Transplantation
3
tislelizumab
2
pegaspargase
2
Whole-Body Irradiation
2
Mycophenolic Acid
2
Microarray Analysis
2
Immunohistochemistry
2
Ifosfamide
2
Gene Expression Profiling
2
Gemcitabine
2
Everolimus
2
Etoposide
2
Cyclosporine
2
Cyclophosphamide
2
Carboplatin
2
Bendamustine Hydrochloride
2
veliparib
1
relatlimab
1
liposomal doxorubicin
1
indolepropanol phosphate
1
gemcitabine-oxaliplatin regimen
1
etoposide phosphate
1
ethanolamine oleate
1
copanlisib
1
aldesleukin
1
WW Domain-Containing Oxidoreductase
1
Vorinostat
1
Vitamin B 12
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma, Extranodal NK-T-Cell
×
Ice
×
Clear all
NCT04425070
2026-01-05
TOUCH
Antengene Corporation
Phase 1/2
Terminated
56 enrolled